AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, a leader in metabolic oncology research and treatment innovation, proudly announces the induction of its co-founder, Dr. Siddhartha Mukherjee, Assistant Professor at Columbia, Pulitzer Prize Winner, and one of Time 100's Most Influential People, into the esteemed National Academy of Medicine (NAM).
Dr. Mukherjee was honored for contributing important research in the immunotherapy of myeloid malignancies, such as Acute Myeloid Leukemia, for establishing international centers for immunotherapy for childhood cancers, and for the discovery of tissue-resident stem cells. His book, “The Emperor of All Maladies,” won the Pulitzer Prize and was nominated by Time as among the century’s 100 most influential books, introducing millions to modern cancer research. This recognition accentuates the collective dedication and caliber of Faeth's team and the company's commitment to advancing the realm of cancer care.
With Dr. Mukherjee's recent induction into the National Academy of Medicine, he joins fellow Faeth co-founders who have previously received this honor from the National Academy of Science: Karen Vousden, PhD, Chief Scientist of CRUK, Group Leader at the Crick Institute, and Director at Bristol Myers Squibb; Lew Cantley, PhD, Professor of Cell Biology at the Dana Farber Cancer Institute at Harvard University; Greg Hannon, PhD, Director of CRUK Cambridge Institute; and Scott Lowe, PhD, Chair of Cancer Biology & Genetics at Memorial Sloan Kettering, underlining the depth of Faeth Therapeutics' commitment to scientific excellence and innovation.
"Dr. Mukherjee's induction into the National Academy of Medicine reaffirms Faeth Therapeutics' dedication to unparalleled scientific rigor and innovation. We are immensely proud to have such an impressive team of co-founders driving our mission to redefine and elevate standards in oncology care," said Anand Parikh, J.D., Chief Executive Officer of Faeth Therapeutics.
Mukherjee is one of 100 new members announced by the academy. In the National Academy of Medicine, members are elected by their colleagues as a testament to their exceptional accomplishments. Being inducted into the academy represents one of the most prestigious accolades within the realm of medicine.
About Faeth Therapeutics
Faeth Therapeutics is a clinical-stage biotechnology company focused on bringing breakthrough research in metabolic oncology into the clinic. The company leverages its machine-learning platform to identify therapeutic programs that combine traditional therapeutics and a dietary metabolic regimen to enhance outcomes, with the goal of transforming the treatment landscape. Lead asset, FTH-001, combines serabelisib and an insulin-suppressing regimen to slow tumor growth via PI3K pathway inhibition. Faeth’s scientific founders include industry leaders Drs. Lew Cantley, Sid Mukherjee, Karen Vousden. For additional information, visit www.faeththerapeutics.com.
